China Poised As Third Major Hurdle For Drug Industry M&As
This article was originally published in PharmAsia News
Executive Summary
China has become the third major commerce area to restrict mergers and acquisitions, signaling a possible problem in China for the proposed takeover by Pfizer of Wyeth. China blocked Coca-Cola's $2.3 billion proposal to buy China Huiyuan Juice Group on grounds the move would reduce competition in the beverage market. By doing so, China joins the United States and the European Union in barring major mergers seen as stifling competition. China's action in the Coca-Cola matter means a third major market hurdle for proposed corporate mergers, including those in the pharmaceutical industry. (Click here for more